Background: There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free
Pancreatic adenocarcinoma is a frequent malignancy with an overall 5-year survival rate of only about 6% (Sant et al, 2009; Siegel et al, 2012) . Its incidence has gradually increased over the past 10 years, and 4360 000 new cases are projected worldwide in 2015 (Globocan). Metastatic pancreatic adenocarcinoma (MPA) is one of the most rapidly lethal gastrointestinal malignancies. Without treatment, the median survival time is consistently o6 months (Hidalgo, 2010) , and new therapeutic options are therefore needed. Since 1997, gemcitabine has been the standard treatment for MPA, giving a median survival of approximately 7 months. Some advances have been made during the past 4 years, including positive results in two phase III trials of first-line Folfirinox (5-fluorouracil, oxaliplatin, irinotecan, leucovorin) (Conroy et al, 2011) and Nab-paclitaxel plus gemcitabine (Von Hoff et al, 2013) . Both Folfirinox and Nab-paclitaxel plus gemcitabine were more effective than gemcitabine alone in terms of progression-free survival (PFS) and overall survival (OS), raising questions as to the treatment choice and sequence. We therefore conducted a multicentre, prospective cohort study to assess the efficacy and tolerability of Nab-paclitaxel plus gemcitabine after failure of first-line Folfirinox in patients with MPA. Folfirinox was administered first because it is currently the standard first-line treatment in France and because guidelines stipulate the need for an Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 0 or 1 and normal bilirubinemia, whereas Nab-paclitaxel plus gemcitabine can be administered to frailer patients.
PATIENTS AND METHODS
Patients. All consecutive MPA patients treated with Nab-paclitaxel plus gemcitabine after Folfirinox failure between February 2013 and July 2014 in 12 French AGEO (Association des GastroEntérologues Oncologues) centres were prospectively enrolled in our database. To be eligible, patients had to be at least 18 years, have an ECOG-PS score of 0, 1 or 2, have histologically or cytologically proven PA with measurable metastatic lesion(s) according to RECIST criteria V1.1 and have received Folfirinox as first-line palliative therapy. The administration of Nab-paclitaxel plus gemcitabine as second-line chemotherapy was decided in each centre, following validation by a multidisciplinary meeting. Patients having received chemotherapy regimens other than Folfirinox were not eligible for the study. As Nab-paclitaxel plus gemcitabine is an approved first-line regimen yielding favourable response and survival rates, and as there is no standard second-line treatment after Folfirinox failure, our institutional review board approved the use of Nab-paclitaxel plus gemcitabine as second-line therapy.
Tumour assessment. The following tumour-related information was collected: date of diagnosis, size of the primary tumour in millimetres, its location (head, body or tail of the pancreas), and the number and location of metastases. Initial evaluation included carbohydrate antigen 19-9 (CA 19-9) assay.
Treatment. The following characteristics of first-line Folfirinox were collected: number of cycles, reasons for treatment cessation, and best response (RECIST v1.1).
Each cycle of Nab-paclitaxel plus gemcitabine consisted of a 60-min intravenous infusion of Nab-paclitaxel at a dose of 125 mg m À 2 , followed by a 30-min infusion of gemcitabine at a dose of 1000 mg m À 2 on days 1, 8, and 15 every 4 weeks, as described for first-line treatment (Von Hoff et al, 2013) . This regimen was delivered until disease progression, unacceptable toxicity or patient refusal.
Primary prophylaxis of neutropenia with granulocyte colonystimulating factor (G-CSF) was left to each physician's discretion.
Outcome measures. Adverse events, the date of the first infusion of Nab-paclitaxel plus gemcitabine and the number of cycles administered were recorded. Tolerability was assessed by recording all chemotherapy-related adverse events that occurred during the study. Nausea and vomiting, diarrhoea, fatigue, sensory neuropathy, hand-foot syndrome, mucositis, alopecia, neutropenia, thrombocytopenia and anaemia were evaluated with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) V4.03. Serious adverse events, including treatment-related deaths, grade 3 or 4 toxicities and withdrawals for toxicity, and dose reductions for adverse events were recorded.
Treatment efficacy was assessed every 2 months by chestabdomen-pelvis computed tomography (CT) using RECIST version1.1 criteria (Therasse et al, 2000) and by CA 19-9 monitoring as recommended by the French national cancer institute and national guidelines. Any third-line chemotherapy administered after disease progression was recorded. After progression, all patients were followed up until death.
Statistical analysis. Patient data were prospectively recorded in the database. Quantitative data were expressed as medians (range) and qualitative data as percentages. As this was a prospective observational cohort, no sample size calculation was necessary. However, we calculated the necessary sample size and halted data collection when it had been reached. Using one-arm nonparametric survival methodology, with 57 patients included over 17 months and with 18 months of follow-up, we would achieve 92% statistical power with a bilateral alpha type 1 error of 5% to demonstrate that the PFS rate at 6 months was 420% (H0), with an expected rate of 40% (H1). Lower and upper critical values would be, respectively, 12% and 34%.
A clinical response was defined as an improvement in symptoms present at the beginning of treatment and was based on the investigators' evaluation. The objective response rate was calculated as the sum of complete and partial responses. The disease control rate was defined as the sum of complete and partial responses and stable disease. In agreement with the DATECAN consensus (Bonnetain et al, 2014) , PFS was defined as the time between the first Nab-paclitaxel plus gemcitabine administration and disease progression or death (all causes), whichever occurred first. OS was defined from the start of Nab-paclitaxel plus gemcitabine chemotherapy until death (all causes). To assess the overall treatment strategy, PFS 1 þ 2 and OS 1 þ 2 were calculated from the beginning of Folfirinox therapy until a corresponding event occurred during or after Nab-paclitaxel plus gemcitabine administration. Patients without events were censored at the last follow-up date. Survival curves were estimated with the KaplanMeier method. Median follow-up was calculated with the reverse Kaplan-Meier method. All analyses were performed with a twosided type 1 error of 5%.
RESULTS
Patient and tumour characteristics. During the recruitment period, 110 patients stopped Folfirinox for progression or toxicity, and 77 (70%) of them were eligible to receive Nab-paclitaxel plus gemcitabine. Twenty patients were excluded from the present study because of locally advanced/non-metastatic disease and two for other reasons (PS42). The study population thus consisted of 57 patients, whose baseline characteristics are summarised in Table 1 . Most patients had an ECOG-PS score of 1 or 2. The median number of Folfirinox cycles received was 12. Nabpaclitaxel plus gemcitabine was usually started because of disease progression (95%). Most tumours were located in the head of the pancreas, and most patients had only one metastatic site.
Tolerability. In September 2014 (cutoff date for this analysis), 248 cycles of Nab-paclitaxel plus gemcitabine had been administered (median per patient: 4, range: 1-12). No toxic deaths occurred. Treatment was stopped in 42 patients (74%) because of disease progression (n ¼ 40) or unacceptable toxicity (n ¼ 2: grade 4 thrombocytopenia; grade 3 asthenia). Toxicities are described in Table 2 . Grade 3-4 toxicities occurred in 21 patients (38%).
Thirty-eight patients (67%) had a transient or permanent dose reduction (gemcitabine 49%, Nab-paclitaxel 64%) because of asthenia (32%), hematological toxicities (45%) or peripheral neurotoxicity (29%). Peripheral neurotoxicity usually consisted of reversible paresthesia and/or hypoesthesia. Seven patients (12.5%) had to stop Nab-paclitaxel permanently because of peripheral neurotoxicity (n ¼ 4), hematological toxicity (n ¼ 2) or asthenia (n ¼ 1).
Efficacy. Patients survival and tumour responses are summarised in Table 3. RECIST assessment was possible in 54 of the 57 patients (1 patient received only two administrations of chemotherapy, and follow-up CT scans were not performed in 2 patients). Objective responses were observed in 10 patients (17.5% in the intention-totreat population (ITT)) and disease stabilisation occurred in 23 patients (40.5%, ITT population), giving a disease control rate of 58% (95% CI: 45-71).
A clinical response was observed in 19 patients (33%), clinical stability in 21 patients (37%) and clinical progression in 17 patients (30%). Symptoms reported before Nab-paclitaxel plus gemcitabine were mainly abdominal pain (33%), asthenia (19%) and ascitis (5%). They were not precisely described for 24 patients (42%). Nab-paclitaxel plus gemcitabine resulted in an improvement in pain and asthenia in 63% of patients.
After a median follow-up of 17.5 months (range 5-45) since the beginning of Folfirinox and 6 months (range 0.7-16 months) since the beginning of Nab-paclitaxel plus gemcitabine, median OS was 8.8 months (95% CI: 6.2-9.7). The OS rates at 6 and 12 months were, respectively, 69% (95% CI: 0.53-0.80) and 15% (95% CI: 0.03-0.36). Median PFS was 5.1 months (95% CI: 3.2-6.2). The PFS rates at 6 and 12 months were, respectively, 39% (95% CI: 0.25-0.52) and 6% (95% CI: 0.01-0.23) (Figure 1 ).
We performed univariate and multivariate analysis to identify factors associated with better outcome in these patients treated with Nab-paclitaxel plus gemcitabine. None of the following factors: age, body mass index, ECOG-PS score (1 or 2 vs 0), number of metastasic sites (2 or 3 vs 1), bilirubin and Ca19-9 levels impacted survival (Supplementary Table S1 ). The response to Nabpaclitaxel plus gemcitabine was not influenced by the prior response to first-line Folfirinox. Indeed, there was no statistical difference in PFS between patients who had a partial response, stable disease or progressive disease as the best response to Folfirinox, and a trend was noted towards worse PFS in patients who previously responded well to Folfirinox. PFS with Nabpaclitaxel plus gemcitabine was significantly better in patients with a PFS value lower than the median with Folfirinox (Supplementary Figure S1) .
Median survival since the beginning of first-line chemotherapy (Folfirinox) was 14 months (95% CI: 12.8-15.4) and 18 months (95% CI: 16-21.2) for PFS 1 þ 2 and OS 1 þ 2 , respectively (Figure 2 ). The OS 1 þ 2 rates at 12 and 24 months were, respectively, 82% (95% CI: 0.68-0.90) and 30% (0.14-0.47). After disease progression on Nab-paclitaxel plus gemcitabine, 15 patients (37.5%) received best supportive care and 25 patients (62.5%) received a third line of chemotherapy. Ten (40%) of the latter patients received a fluoropyrimidine plus a platinum salt (oxaliplatin or cisplatin): 5 patients (20%) received Folfirinox; 3 patients (12%) received a Folfiri-3 regimen; 2 patients (8%) received gemcitabine plus erlotinib; and 5 patients (20%) received other regimens in early-phase clinical trials.
DISCUSSION
There is no consensus second-line chemotherapy regimen (Rahma et al, 2013) for MPA patients, and the second-line treatment choice should take into account the first-line treatment, of which several effective options are available, including Folfirinox (Conroy et al, 2011) and Nab-paclitaxel plus gemcitabine (Von Hoff et al, 2013) . Indeed, these two regimens have not been compared in the firstline setting. Biomarkers (hENT1and ERCC1) (Maréchal et al, 2012; Peters et al, 2014) might help to choose between first-line gemcitabine-or platinum-based regimens but have not yet been validated. This means that currently the best first-line treatment and the therapeutic sequence are unknown and our daily practice is guided solely by patient characteristics. In this context, we decided to study the sequence used in many centres, notably in France, namely first-line Folfirinox followed by gemcitabine-based second-line chemotherapy. Strategies based on Folfirinox followed by Nab-paclitaxel plus gemcitabine, or the reverse sequence, have not previously been tested. Folfirinox seems easier to administer first, when patients are still in relatively good general condition, including normal bilirubinemia, while Nab-paclitaxel plus gemcitabine may be a better-tolerated option for more fragile patients, notably those with a Karnofsky index of 70-80% (Von Hoff et al, 2013) . In addition, the acceptable tolerability of Nab-paclitaxel plus gemcitabine, together with a few reports of efficacy in second-line treatment (Portal et al, 2014; Giordano et al (2014) ), makes it a good candidate treatment for patients having received Folfirinox. In our selected patient population, the observed median PFS and OS with Nab-paclitaxel plus gemcitabine were, respectively, 5.1 and 8.8 months. We confirmed our statistical hypothesis, with a 6-month PFS of 39% (95% CI: 0.25-0.52). Moreover, median OS from the beginning of first-line treatment was 18 months. Although our strategy seems very promising, we cannot compare survival with that of other first-line trials, as we selected only patients able to receive first-line Folfirinox and a relatively intensive second-line treatment. Interestingly, the response to first-line Folfirinox did not influence the response to Nab-paclitaxel plus gemcitabine. The disease control rate was 58%. With a median follow-up of 6 months, 39% and 6% of patients were still controlled at 6 and 12 months, respectively. Among patients who progressed, 62.5% received a third line of chemotherapy.
Many drugs have been tested in second-line chemotherapy regimens for MPA, in phase II and even phase III trials. The results are summarised in Table 4 . 5-FU, folinic acid and oxaliplatin (42) 15 ( combinations (OFF or FOLFOX) (Yoo et al, 2009; Pelzer et al, 2011; Oettle et al, 2014; Zaanan et al, 2014) had the best supporting evidence after failure of gemcitabine-based first-line treatment, despite some recent controversy (Gill et al, 2014) . It should be noted that the two regimens used in these trials were slightly different, especially concerning the 5-FU dosage and administration. This may have had a role in the different outcomes reported in these two studies. In selected populations, Folfirinox has been tested in two retrospective studies, with an OS of about 8.5 months (Assaf et al, 2011; Lee et al, 2013) . Recently, the NAPOLI-1 trial showed the superiority of a combination of 5-FU and MM-398 (injectable liposomal irinotecan) over 5-FU alone (Von Hoff et al (2014) ). In the FFCD 0301 trial, gemcitabine was well tolerated as second-line therapy after a 5-FU-platinum doublet (Dahan et al, 2010) , but median PFS was only 2.3 months (95% CI 1.9-3). Two recent phase II trials tested second-line taxane therapy. In the first, PFS and OS were 3.7 and 5.3 months, respectively, with the capecitabine-docetaxel combination (Soares et al, 2014) . In the second, PFS and OS were 1.7 and 7.3 months, respectively, with Nab-paclitaxel monotherapy (Hosein et al, 2013) . Therefore, within the limits of an indirect comparison, OS and PFS appear to be better with second-line Nab-paclitaxel plus gemcitabine. No toxic deaths occurred in patients receiving Nab-paclitaxel plus gemcitabine. Grade 3-4 toxicities occurred in 21 patients (37.5%) and consisted mainly of haematological adverse effects (neutropenia: 12.5%; thrombocytopenia: 6.5%; anaemia: 3.5%), asthenia (9%) and neurotoxicity (12.5%). These results are comparable with those reported with Nab-paclitaxel plus gemcitabine first-line chemotherapy (Von Hoff et al, 2013) and with other second-line regimens (10-38% of grade 3-4 toxicity). One of the main concerns with our therapeutic sequence is the risk of severe chronic peripheral sensory neurotoxicity owing to the use of neurotoxic agents such as Nab-paclitaxel after oxaliplatin. Neuropathy has been reported in 4% of patients treated with second-line taxane-based regimens (Soares et al, 2014) and in 0-7.5% of patients treated with oxaliplatin-based regimens (Yoo et al, 2009; Pelzer et al, 2011; Oettle et al, 2014; Zaanan et al, 2014) . Severe sensory neurotoxicity affected 12.5% of our patients and led to permanent Nab-paclitaxel discontinuation in five cases. This toxicity rate is quite low compared with the MPACT trial, even though our patients were receiving second-line treatment. As this was an observational study, dose modifications were not standardised and dose reductions were made earlier than during first-line treatment. Indeed, as this was second-line therapy, and as there was a confounding aetiology of neuropathy (oxaliplatin or Nab-paclitaxel), drug management was more cautious than in the first-line setting. Nab-paclitaxel was reduced or stopped earlier and more frequently than in the MPACT trial. Indeed, the Nabpaclitaxel dose was reduced in 54% of patients (compared with 41% in MPACT), and only 59% of all Nab-paclitaxel administrations involved the full dose (71% in MPACT). Furthermore, the mechanisms of oxaliplatin and Nab-paclitaxel neurotoxicity are different, and so is their reversibility. Oxaliplatin causes symmetrical paresthesia and distal hypoesthesia that can lead to difficulties in daily life activities, and this toxicity can worsen even after treatment cessation and last for several years. Nab-paclitaxel also causes paresthesia, as well as distal burning pain, but the symptoms generally improve within 2 months after treatment cessation (Scripture et al, 2006) . Therefore, despite an equivalent grade, the impact of Nab-paclitaxel neurotoxicity on patients' quality of life may be less severe. This is supported by the results of Safran et al (2014) showing that patients treated with a combination of FOLFOX and Nab-Paclitaxel did not develop significant neuropathy when they received fewer than 10 cycles, which is consistent with the occurrence of neuropathy with FOLFOX alone. With a median of less than 5 cycles per patient in our study, the risk seems limited.
The main limitation of this prospective multicentre study is its observational nature. Treatment decisions, such as dose reductions and prophylactic use of G-CSF, were left to the discretion of the physicians in different centres, as was treatment discontinuation. These decisions could have impacted the efficacy and safety results. Moreover, our population was highly selected, as patients had to be able to receive first-line Folfirinox and only patients with a ECOG-PS of 0, 1 or 2 after Folfirinox failure were enrolled. Altogether, 63% of the patients treated with first-line Folfirinox and with a metastatic disease were eligible for the present study. This percentage compares favourably with o50% reported Second-line gemcitabine plus Nab-paclitaxelelsewhere. Our patients seem representative of the general population of patients in this setting. Indeed, Folfirinox is widely used as first-line treatment in France, and o50% of patients treated for pancreatic adenocarcinoma are reported to be eligible for second-line treatment (Bachet et al, 2009) , whatever the firstline regimen, even among selected patients from the most recent therapeutic trials (Conroy et al, 2011; Von Hoff et al, 2013) .This selection bias seems to be a consistent feature of second-line studies and also in routine clinical practice. We enrolled patients with an ECOG-PS of 2, without strong exclusion criteria, contrary to many previous studies. Another limitation of our study is the lack of quality-of-life evaluation, which is an important element of palliative chemotherapy for pancreatic cancer.
CONCLUSION
With a median PFS of 5.1 months and a median OS of 8.8 months, the Nab-paclitaxel and gemcitabine combination seems promising for second-line treatment of patients with MAP who are in good general condition after Folfirinox failure. The main adverse effects are peripheral neuropathy, neutropenia, thrombocytopenia and fatigue. These promising results need to be confirmed in a comparative randomised trial.
